Skip to content

How Reviewers Score

A strong peer review score doesn't guarantee an award. Recommended applications go to a second review by the institute's national Advisory Council. NIH then weighs scientific merit against available funds, the project's fit with institute priorities and any security risk found through the HHS Due Diligence Program (PA-27-100). Of those factors, only merit can be shaped on the page, and reviewers build it from five separate scores and one overall impact score.

Five Scored Criteria

Each criterion gets its own score, but NIH tells reviewers an application doesn't have to be strong in all five. It even notes that a project with little innovation may still be what a field needs to advance.

  • Significance - reviewers ask whether the product meets an important unmet need and how clinical practice will change if the aims succeed. Leuko Labs answers with 850,000 patients a year and $6.4 billion in costs before it describes the device.
  • Investigators - once a project nears market, the scientific résumé is no longer enough. For later-stage work, reviewers also ask whether the team has the expertise to commercialize the product.
  • Innovation - Phase II and Fast-Track reviewers ask for a credible plan to put a time barrier between the company and rivals building a similar solution. Intellectual property protection is part of that answer.
  • Approach - a Phase II application has to show progress against Phase I objectives, or their equivalent for a Direct to Phase II. Rivanna's request rests on NIH-funded navigation work completed before the award.
  • Environment - the business setting counts alongside the lab. A Phase I company is asked whether it has business expertise and resources, or has identified where it will find them.

Commercialization Plan Questions

Reviewers of Phase II and Fast-Track applications weigh the Commercialization Plan in the overall impact score, though it gets no score of its own. Their first question is whether the company understands the barriers between its product and the market, such as regulatory approval, insurance reimbursement, competing products and customer preferences, and has a strategy for each. Leuko Labs builds two of those strategies into its aims, a De Novo submission to FDA and an outcomes study to support reimbursement. Nest Genomics avoided the reimbursement question by starting where payer coverage already exists.

Reviewers also look for post-SBIR milestones, a funding plan and any letters of interest or commitment that back it. Venture-backed companies should expect one more question. Where a project duplicates well-funded private development, reviewers ask why federal money is needed despite the private investment already behind it.

After Review

A Just-in-Time request asks for information before an award decision. NIH states that the request is neither a Notice of Award nor an indicator of possible funding. Hold back on new hires and spending until the Notice of Award arrives, because any costs incurred before then are at your own risk.